Wanbury Share Price

274.5518.61 (7.27%)

Closed
As On: 12 Jun, 2026, 04:06 PM IST
As On: 12 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	261.00
High	284.00
Low	255.90
Prev Close	255.95
Volume	1,75,811
VWAP(₹)	270.66

Share Price	Value
Today/Current/Last	274.55273.00
Previous Day	255.95256.05

Wanbury Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Wanbury Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Jul 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024
Total Income	163.53	173.84	134.29	162.82	132.05
Total Income Growth (%)	-5.93	29.45	-17.52	23.30	-5.90
Total Expenses	142.39	145.75	122.83	144.51	123.42
Total Expenses Growth (%)	-2.31	18.66	-15.00	17.08	24.71
EBIT	21.15	28.10	11.46	18.32	8.63
EBIT Growth (%)	-24.74	145.20	-37.44	112.24	-79.14
Profit after Tax (PAT)	13.49	20.26	1.22	8.02	1.04
PAT Growth (%)	-33.40	1,563.50	-84.81	672.95	-96.92
EBIT Margin (%)	12.93	16.16	8.53	11.25	6.54
Net Profit Margin (%)	8.25	11.65	0.91	4.92	0.79
Basic EPS (₹)	4.12	6.18	0.38	2.44	0.32

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	164.79	162.63	160.26	163.53	173.84
Total Income Growth (%)	1.33	1.48	-2.00	-5.93	29.45
Total Expenses	141.56	139.50	137.98	142.39	145.75
Total Expenses Growth (%)	1.48	1.10	-3.09	-2.31	18.66
EBIT	23.23	23.12	22.28	21.15	28.10
EBIT Growth (%)	0.44	3.79	5.36	-24.74	145.20
Profit after Tax (PAT)	21.70	15.76	15.18	13.49	20.26
PAT Growth (%)	37.73	3.81	12.53	-33.40	1,563.50
EBIT Margin (%)	14.10	14.22	13.90	12.93	16.16
Net Profit Margin (%)	13.17	9.69	9.47	8.25	11.65
Basic EPS (₹)	7.26	4.52	4.58	4.12	6.18

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	603.01	578.64	500.56	512.69	394.92
Total Revenue Growth (%)	4.21	15.60	-2.37	29.82	7.14
Total Expenses	573.46	547.86	510.25	507.93	407.33
Total Expenses Growth (%)	4.67	7.37	0.46	24.70	5.37
Profit after Tax (PAT)	30.53	55.96	-10.40	81.47	-12.61
PAT Growth (%)	-45.44	-	-112.76	-	-119.56
Operating Profit Margin (%)	11.09	10.41	2.34	4.96	2.71
Net Profit Margin (%)	5.09	9.72	-2.08	15.93	-3.21
Basic EPS (₹)	9.32	17.10	-3.18	25.29	-5.04

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	651.21	603.01	578.64	500.56	512.69
Total Revenue Growth (%)	7.99	4.21	15.60	-2.37	29.82
Total Expenses	587.80	573.46	547.86	510.25	507.93
Total Expenses Growth (%)	2.50	4.67	7.37	0.46	24.70
Profit after Tax (PAT)	66.13	30.53	30.40	-10.40	81.47
PAT Growth (%)	116.62	0.43	-	-112.76	-
Operating Profit Margin (%)	14.36	11.09	10.41	2.34	4.96
Net Profit Margin (%)	10.17	5.09	5.28	-2.08	15.93
Basic EPS (₹)	20.48	9.32	9.29	-3.18	25.29

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 6.16% of its operating revenues towards interest expenses and 17.39% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	413.92	343.49	303.87	352.55	289.18
Total Assets Growth (%)	20.50	13.04	-13.81	21.91	3.76
Total Liabilities	354.65	315.55	336.69	375.97	445.42
Total Liabilities Growth (%)	12.39	-6.28	-10.45	-15.59	5.51
Total Equity	59.27	27.94	-32.82	-23.42	-156.24
Total Equity Growth (%)	112.13	-	-	-	-
Current Ratio (x)	1.11	0.74	0.39	0.48	0.28
Total Debt to Equity (x)	2.92	3.94	-1.95	-2.86	-0.57
Contingent Liabilities	67.06	70.29	1,033.26	908.54	889.88

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	517.67	413.92	343.49	302.25	351.00
Total Assets Growth (%)	25.07	20.50	13.64	-13.89	22.04
Total Liabilities	373.22	354.65	315.55	309.50	348.81
Total Liabilities Growth (%)	5.24	12.39	1.95	-11.27	-16.60
Total Equity	144.45	59.27	27.94	-7.26	2.19
Total Equity Growth (%)	143.72	112.13	-	-431.51	-
Current Ratio (x)	1.19	1.11	0.74	0.42	0.52
Total Debt to Equity (x)	1.49	2.92	3.94	-8.84	30.64
Contingent Liabilities	0.00	67.06	70.29	945.26	908.54

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	26.10	3.98	19.80	40.52	16.68
Net Cash used in Investing Activities	-51.17	-16.63	-8.84	0.59	8.04
Net Cash flow from Financing Activities	25.73	14.55	-31.99	-28.58	-17.39
Net Cash Flow	0.66	1.91	-21.03	12.53	7.34
Closing Cash & Cash Equivalent	4.06	3.40	1.49	22.53	10.00
Closing Cash & Cash Equivalent Growth (%)	19.42	127.54	-93.37	125.23	275.84
Total Debt/ CFO (x)	6.64	27.64	3.24	1.65	5.30

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	31.53	26.10	4.02	19.80	40.52
Net Cash used in Investing Activities	-56.40	-51.17	-16.63	-8.84	0.59
Net Cash flow from Financing Activities	22.42	25.73	14.55	-31.99	-28.58
Net Cash Flow	-2.45	0.66	1.94	-21.03	12.53
Closing Cash & Cash Equivalent	1.61	4.60	3.40	1.46	22.49
Closing Cash & Cash Equivalent Growth (%)	-64.97	35.30	133.59	-93.53	125.72
Total Debt/ CFO (x)	6.83	6.64	27.37	3.24	1.65

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 31.53 cr is 0.48 times compared to the reported net profit of Rs 66.13 cr. (Source: Standalone Financials)
Increase in Cash from Investing
Company has used Rs 56.4 cr for investing activities which is an YoY increase of 10.22%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	51.50	200.26	0.00	-347.88	0.00
Return on Capital Employed (%)	27.78	46.34	-70.89	-351.22	-16.12
Return on Assets (%)	7.37	16.29	-3.42	23.10	-4.35
Interest Coverage Ratio (x)	2.16	2.50	1.13	1.79	0.89
Asset Turnover Ratio (x)	1.58	1.78	1.52	1.60	1.39
Price to Earnings (x)	25.19	8.54	-11.75	3.41	-16.47
Price to Book (x)	12.97	17.09	-3.72	-11.86	-1.33
EV/EBITDA (x)	11.64	7.97	7.57	8.67	13.92
EBITDA Margin (%)	13.31	12.67	4.82	7.20	5.20

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	45.78	51.50	108.79	0.00	3,724.18
Return on Capital Employed (%)	29.49	27.78	46.34	129.25	138.00
Return on Assets (%)	12.77	7.37	8.85	-3.43	23.21
Interest Coverage Ratio (x)	3.59	2.16	2.50	1.13	1.79
Asset Turnover Ratio (x)	1.40	1.58	1.78	1.53	1.60
Price to Earnings (x)	11.76	25.19	15.72	-11.75	3.41
Price to Book (x)	5.38	12.97	17.09	-16.82	127.06
EV/EBITDA (x)	9.15	11.64	7.97	7.57	8.67
EBITDA Margin (%)	16.56	13.31	12.67	4.82	7.20

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Wanbury Ltd	14.50	16.19	51.50	27.78	7.37	9.07	11.09	5.09	9.32	1.11	2.92	6.64
Venus Remedies	23.37	3.62	15.48	19.39	12.03	11.28	17.43	13.35	76.89	2.44	0.00	0.00
NGL Fine Chem	39.21	5.72	14.61	17.15	8.82	21.81	13.54	9.60	77.90	1.84	0.33	2.50
Ind-Swift Labs	34.18	1.02	2.99	4.33	2.47	-17.67	9.58	6.44	4.95	3.83	0.01	-0.28
Lincoln Pharma	14.50	1.68	11.60	14.96	9.87	9.66	17.38	13.09	43.88	5.25	0.01	0.04
Add More

Annual Ratios (%)

Choose from Peers

Themis Medicare
Kopran Ltd
Anuh Pharma
Kilitch Drug
Albert David

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Wanbury Ltd Stock Performance	7.27	6.19	6.29	1.70	-5.91	470.20	166.94
Venus Remedies Stock Performance	4.81	91.69	75.54	136.72	413.72	797.40	460.32
NGL Fine Chem Stock Performance	12.24	34.21	35.02	29.94	137.15	100.55	0.00
Ind-Swift Labs Stock Performance	2.78	21.11	13.26	14.90	126.62	133.90	95.71
Lincoln Pharma Stock Performance	1.03	-4.50	4.60	2.17	5.05	44.16	94.32
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	1,50,29,561	43.02 %	-0.04
Pledge	93,46,073	62.18 %	0.00
FII	2,05,145	0.59 %	-0.13
DII	895	0.00 %	0.00
MF	895	0.00 %	0.00
Others	1,97,03,797	56.38 %	0.17

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	43.02	43.07	39.63	39.63
Pledge	62.18	62.18	71.73	76.74
FII	0.59	0.72	0.79	1.59
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	56.38	56.21	59.58	58.77

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.03536498%
  % of AUM
- -3.70
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.04%
  % of AUM
- 5.98
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Board Meeting
Audited Results
May 12, 2026
Board Meeting
Audited Results
May 12, 2026
Board Meeting
Quarterly Results
Jan 28, 2026

Board Meetings

Announced on	Meeting on
May 12, 2026	May 29, 2026
Audited Results
May 12, 2026	May 14, 2026
Audited Results
Jan 28, 2026	Feb 05, 2026
Quarterly Results
Nov 06, 2025	Nov 13, 2025
Quarterly Results
Jul 28, 2025	Aug 04, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 31, 2010 Jul 29, 2010 10%
Dec 31, 2008 Mar 12, 2009 5%
Jun 29, 2007 Sep 13, 2007 20%
Jun 28, 2006 Sep 07, 2006 15%
Jan 31, 2006 Feb 20, 2006 5%
Bonus
No Data Available
Splits
No Data Available
Rights
Announced on Ex-Date
Sep 02, 1994 -
Rights ratio: 1 share for every 1 held at a price of Rs 10.0
AGM/EGM Meetings
Announced on Meeting on
Dec 12, 2025 Jan 05, 2026
-
Aug 28, 2025 Sep 18, 2025
-
Jan 24, 2025 Feb 20, 2025
Book closure from Feb 14, 2025 to Feb 20, 2025
Sep 17, 2024 Sep 27, 2024
A.G.M.
Oct 26, 2023 Nov 18, 2023
-

Announced on	Ex-Date	Dividend%
May 31, 2010	Jul 29, 2010	10%
Dec 31, 2008	Mar 12, 2009	5%
Jun 29, 2007	Sep 13, 2007	20%
Jun 28, 2006	Sep 07, 2006	15%
Jan 31, 2006	Feb 20, 2006	5%

Announced on	Ex-Date
Sep 02, 1994	-
Rights ratio: 1 share for every 1 held at a price of Rs 10.0

Announced on	Meeting on
Dec 12, 2025	Jan 05, 2026
-
Aug 28, 2025	Sep 18, 2025
-
Jan 24, 2025	Feb 20, 2025
Book closure from Feb 14, 2025 to Feb 20, 2025
Sep 17, 2024	Sep 27, 2024
A.G.M.
Oct 26, 2023	Nov 18, 2023
-

About Wanbury

Wanbury Ltd., incorporated in the year 1988, is a Small Cap company (having a market cap of Rs 959.26 Crore) operating in Pharmaceuticals sector.

Wanbury Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Export Incentives and Scrap for the year ending 31-Mar-2025.

For the quarter ended 30-06-2025, the company has reported a Consolidated Total Income of Rs 163.53 Crore, down 5.93 % from last quarter Total Income of Rs 173.84 Crore and up 23.84 % from last year same quarter Total Income of Rs 132.05 Crore. Company has reported net profit after tax of Rs 13.49 Crore in latest quarter.

The company’s top management includes Mr.K Chandran, Mr.Mohan Kumar Rayana, Ms.Anupama Vaidya, Mr.Manojkumar K Gursahani, Mr.Mridul Sumanlal Mehta, Mr.P V Sankar Dass, Mr.Vinod Verma, Mr.Jitendra J Gandhi. Company has V Parekh & Associates as its auditors. As on 31-03-2026, the company has a total of 3.49 Crore shares outstanding.

Wanbury Ltd Share Price Today is Rs. 274.55. On previous day, the Wanbury Ltd Share Price (NSE) closed at Rs. 255.95, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 43.02% of the stake in Wanbury Ltd shares, out of which 62.18% was pledged. On the same date, foreign institutional investors' (FII) holdings of Wanbury Ltd stocks was 0.59% as compared to 0.72% in Dec 2025 with decrease of 0.13%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Wanbury Ltd shares 0.0% was held by mutual funds. The rest including public held is 56.39%. Wanbury Ltd stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Wanbury Ltd Dividend: Ever since 1988, Wanbury Ltd dividends has been paid out around 7 times. As on 12 Jun, 2026, 04:06 PM IST, The overall dividend yield for Wanbury Ltd stands at 0.0%. The last dividend paid was on February 20, 2006 (Rs. 0.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 18.93.

Wanbury Ltd Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 164.79 Cr. of sales and 1.33% of quarterly net profit, there have been multiple ups and downs in the Wanbury Ltd stock prices in the past few weeks. For example, Wanbury Ltd stock price on 5th of June 2026 was around Rs. 262.3. Wanbury Ltd share price now stands at an average of Rs. 274.55. Judging by last week's performance, stock is in down trend.

Wanbury Ltd has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Wanbury Ltd share.

Historical Prices and Performance:
Wanbury Ltd, incorporated in 1988 is a Small Cap company (with a market cap of Rs. 959.26) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Wanbury Ltd stock was 45.78%, 51.5%, 200.26%, 0.0% and -347.88% respectively.
The Wanbury Ltd share gave a 3 year return of 392.47% as compared to Nifty 50 which gave a return of 26.99%.
Wanbury Ltd announced 5.0% final dividend on February 20, 2006.

Key Metrics:
PE Ratio of Wanbury Ltd is 13.52
Prices/Sales Ratio of Wanbury Ltd is 1.28
Price/Book Ratio of Wanbury Ltd is 15.09

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Wanbury Ltd, major competitors and peers include Venus Remedies, NGL Fine Chem, Ind-Swift Labs and Lincoln Pharma. As of Dec 2025, the dividend yield of Wanbury Ltd stands at 0.0% while Venus Remedies, NGL Fine Chem, Ind-Swift Labs and Lincoln Pharma stand at 0.56%, 0.06%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 13.52 and 15.09 respectively.

Leadership of Wanbury Ltd :
Jitendra J Gandhi is Co. Secretary & Compl. Officer
Vinod Verma is Chief Financial Officer
K Chandran is Whole Time Director
Mohan Kumar Rayana is Whole Time Director
Anupama Vaidya is Ind. Non-Executive Woman Director
Mridul Sumanlal Mehta is Ind. Non-Executive Director
P V Sankar Dass is Ind. Non-Executive Director
Manojkumar K Gursahani is Ind. Non-Executive Director

Industry

Pharma - Indian

Key Indices Listed On

BSE Healthcare

Address

BSEL Tech Park,B-Wing, 10th Floor, Sector 30-A,Opp. Vashi Railway Station,New Mumbai, Maharashtra - 400703

Contact

cs@wanbury.com

http://www.wanbury.com

PE Ratio(x)	14.50
EPS - TTM(₹)	18.93
MCap(₹ Cr.)	959.26
MCap Rank	90
PB Ratio(x)	15.32
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	320.95
52W Low(₹)	161.50
MCap/Sales	1.28
Beta(1 Month)	0.60
BV/Share(₹)	16.96

PE Ratio(x)	14.42
EPS - TTM(₹)	18.93
MCap(₹ Cr.)	953.85
MCap Rank	91
PB Ratio(x)	15.16
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	329.00
52W Low(₹)	162.00
MCap/Sales	1.28
Beta(1 Month)	-0.25
BV/Share(₹)	16.96

1 Day	7.27%
1 Month	10.22%
3 Months	6.68%
1 Year	-8.67%
3 Years	392.47%
5 Years	162.73%

1 Day	6.61%
1 Month	9.05%
3 Months	5.98%
1 Year	-8.8%
3 Years	386.72%
5 Years	162.63%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Wanbury Share Price

Key Metrics

Wanbury Ltd share price insights

Wanbury Ltd Share Price Returns

Wanbury Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Motilal Oswal BSE Healthcare ETF-G

Bandhan BSE Healthcare Index Direct-G

Wanbury Ltd Top Searches

Corporate Actions

About Wanbury

Executive Leadership

Auditors

FAQs about Wanbury share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News